AUG 13, 2026 · PHASE 1/2 TRIAL
A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1
ClinicalTrials.gov
This is a Phase 1/2 trial registration with no results posted; it describes planned enrollment and primary outcome measures but reports no clinical data, efficacy, or safety findings.
Reported
Planned enrollment104
PhasePhase 1, Phase 2
Primary outcome (Dose Escalation)…At the end of Cycle 1 (21 days)